Andrew Badrot

Andrew Badrot is the founder and CEO of C2 PHARMA, an Irish-based pharmaceutical group established in 2014 following the acquisition of a product portfolio of active pharmaceutical ingredients (APIs) from Boehringer Ingelheim. Today, C2 PHARMA is the preeminent ophthalmic API manufacturer and distributes its APIs and complex chemical compounds obtained from synthetic and natural sources globally. Along with C2 Pharma, he founded Logistics4Pharma, a full-fledged GDP-compliant logistics service provider based in Frankfurt (Germany) as well as ASM Research Chemicals, a contract research and development services supplier based in Hanover (Germany). Andrew oversees the seamless coordination of C2 Pharma’s activities from API manufacturing and distribution to product lifecycle management, pharma logistics and R&D-scale contract synthesis services. He has a wide range of expertise in the pharmaceutical industry and has worked previously at Lonza (Switzerland), SCHOTT(Germany), and Sun Microsystems (California) before starting C2 Pharma in 2014. Andrew has a degree in Engineering Economic Systems and Operations Research from Stanford University (USA) and an engineering degree in Nuclear Physics from Institut Polytechnique (France).